Abstract: The present invention relates to a therapeutic substance delivery device for delivering a therapeutic substance to a desired site in a bodily duct, characterized in that the therapeutic substance delivery device is provided with: a therapeutic substance loading portion; a connector which is connected to the therapeutic substance loading portion; and a supplying/discharging pipe connected to the connector; and in that the therapeutic substance loading portion includes a main body portion in which a recessed portion is formed, a resilient film, and a connecting pipe; the connector is provided with a joint main body, a flange portion fixed to the other end portion side of the joint main body, and a fixing nut through which the joint main body passes; the joint main body is provided with a tube fastening portion; and at least part of the inner wall of the fixing nut is provided with a thread.

Abstract: S100A8-inhibiting peptides include (A) a peptide of 5 to 10 residues in length containing a fifth alanine (Ala) from an N-terminus in an amino acid sequence of SEQ ID NO: 1, or (B) a peptide consisting of an amino acid sequence of SEQ ID NO: 2.

Abstract: The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45° C., (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45° C.; and also provides a layered cell sheet obtained by the method.

Abstract: The present invention provides a production method for a composition for cell culturing. This production method comprises: (1) a step for subjecting algae to an acid hydrolysis treatment and/or an alkali hydrolysis treatment; (2) a step for neutralizing the hydrolysis product obtained in the step (1) to obtain an algae extract; and (3) a step for mixing the algae extract with a medium for cell culturing, wherein the medium for cell culturing does not substantially contain L-glutamine.

Abstract: The present invention provides a tubular tissue preparation device provided with: a chamber for accommodating a tubular support body; a first support part for communicating the inside and the outside of the chamber and fixing the tubular support body; and a pressurizing/depressurizing means for controlling the pressure in an inner space of the chamber, wherein the first support part is for fixing a first opening section of the tubular support body, communicating a lumen of the tubular support body and the outside of the chamber, and separating the lumen of the tubular support body and the inner space of the chamber. Also, the present invention provides a tubular tissue preparation kit that includes said device and a device for transporting sheet-shaped tissue. In addition, the present invention provides a tubular tissue preparation method using said device.

Abstract: Disclosed is a method for acquiring information on spinal muscular atrophy, comprising acquiring a fluorescence image of a nucleated cell in a measurement sample, wherein the measurement sample is a sample prepared from a blood specimen obtained from a subject, an SMN protein in the nucleated cell is labeled with a first fluorescent dye, and a predetermined nuclear protein in the nucleated cell is labeled with a second fluorescent dye, acquiring an intracellular distance between a first bright spot corresponding to the first fluorescent dye and a second bright spot corresponding to the second fluorescent dye in the fluorescence image, and acquiring a value regarding a number of nucleated cells in which the intracellular distance is equal to or less than a first threshold value, wherein the value is an indicator of spinal muscular atrophy affection.

Abstract: Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.

Abstract: A device for measuring a tension of a sheet-like tissue containing cardiomyocytes includes a first gel adapter holder having a frame member and a first gel holding member protruding toward a part of an inside face of the frame member for fixing one end of a film-like gel; and a second gel adapter holder having a second gel holding member for fixing the other end of the gel and a connection member connected to the second gel holding member. A kit includes the tension measuring device; a substrate having a pair of gel molding protruding members fitted along the inside face of the frame member; and a gel forming lid body having a face parallel to a gel contact face of the substrate so as to form an upper face of the gel. Further, a system for measuring the tension includes the tension measuring device.

Abstract: A sheet for covering a wound includes a laminate of a serosal membrane and a cell sheet. The sheet for covering a wound has a proper thickness and strength. The sheet does not flow out from the wound site and can be fixed to the wound site by suture or anastomosis, if necessary. The sheet can be stably engrafted onto a wound region.

Abstract: The present invention provides an angiogenesis inhibitor containing as an active ingredient LYPD1 protein or a derivative thereof, a part thereof, or a vector expressing the same, or a cell expressing the same. The present invention also provides a screening method for angiogenesis inhibitors that enhance the expression of LYPD1 protein wherein the method includes (i) a step for treating a first cell by a test substance and culturing and (ii) a step for detecting the expression level of LYPD1 protein from the first cell and comparing with the level of LYPD1 protein of an untreated first cell.

Abstract: An object of the present invention is to obtain a thicker animal cell composition by a simple and less expensive method. Namely, an object of the present invention is to provide a method for culturing a thicker animal cell composition by eliminating the hypoxia associated with animal cell compositions, a method for producing an animal cell composition containing unicellular algae, and an animal cell composition. The present invention provides a method for culturing an animal cell composition in a culture medium in the presence of unicellular algae and under exposure to light. According to the method of the present invention, oxygen can be continuously supplied in the culture medium, cell damage is alleviated, and a thicker cell composition can be obtained in the absence of a capillary network.

Abstract: One embodiment of the present disclosure is provided with: an information acquisition portion; an information storage portion; an event extraction section; a region setting section; and a display section. The information storage portion adds, to medical information, a time at which the information acquisition portion acquires the medical information from each of multiple medical devices used in a surgery, and a label for specifying the medical information. The display section causes a display device to display, as medical information, an image including a surgery site and at least one event extracted by the event extraction section in a time region set by the region setting section based on the time added to the medical information.

Abstract: The present invention provides a tubular tissue preparation device provided with: a chamber for accommodating a tubular support body; a first support part for communicating the inside and the outside of the chamber and fixing the tubular support body; and a pressurizing/depressurizing means for controlling the pressure in an inner space of the chamber, wherein the first support part is for fixing a first opening section of the tubular support body, communicating a lumen of the tubular support body and the outside of the chamber, and separating the lumen of the tubular support body and the inner space of the chamber. Also, the present invention provides a tubular tissue preparation kit that includes said device and a device for transporting sheet-shaped tissue. In addition, the present invention provides a tubular tissue preparation method using said device.

Abstract: The present invention relates to a therapeutic substance delivery device for delivering a therapeutic substance to a desired site in a bodily duct, characterized in that the therapeutic substance delivery device is provided with: a therapeutic substance loading portion; a connector which is connected to the therapeutic substance loading portion; and a supplying/discharging pipe connected to the connector; and in that the therapeutic substance loading portion includes a main body portion in which a recessed portion is formed, a resilient film, and a connecting pipe; the connector is provided with a joint main body, a flange portion fixed to the other end portion side of the joint main body, and a fixing nut through which the joint main body passes; the joint main body is provided with a tube fastening portion; and at least part of the inner wall of the fixing nut is provided with a thread.

Abstract: The presently disclosed subject matter is to provide a hepatocyte structure, particularly, a hepatocyte structure that mimics nonalcoholic steatohepatitis (NASH). A hepatocyte construct including an aggregate containing hepatocytes and adherent cells that are non-hepatocytes, and wherein the hepatocytes include ballooned hepatocytes is provided. Further, a method for producing a hepatocyte construct, comprising: (i) forming an aggregate by aggregating a cell group comprising hepatocytes and adherent cells that are non-hepatocytes; and (ii) culturing the aggregate is provided.

Abstract: A cell culture system having a cell culture vessel, a composition controlling fluid storage vessel, a culture fluid composition controlling means having an inlet and an outlet for a cell culture fluid, an inlet-connected fluid feeding circuit from the cell culture vessel to the inlet of the culture fluid composition controlling means, an outlet-connected fluid feeding circuit from the cell culture vessel to the outlet of the culture fluid composition controlling means, a means which perfuses the cell culture fluid from the inlet-connected fluid feeding circuit to the outlet-connected fluid feeding circuit through the culture fluid composition controlling means, and a means which controls the amount of fluid in the cell culture vessel, in which compositions of the cell culture fluid in the cell culture vessel and compositions of the composition controlling fluid in the composition controlling fluid storage vessel can be controlled in a continuous manner.

Abstract: The present invention pertains to a method for culturing a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells at a temperature of 40.5° C. or higher and reducing the pluripotent stem cells included in the cell population. The present invention also pertains to a method for reducing pluripotent stem cells from a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells, wherein the method includes a step for activating the TRPV-1 expressed in the pluripotent stem cells included in the cell population. The present invention makes it possible to reduce the pluripotent stem cells remaining in an undifferentiated state when inducing the differentiation of a pluripotent stem cell population.

Abstract: The present invention provides a method of inhibiting progression of or preventing renal disorder, the method comprising applying a cell sheet composition for inhibiting progression of or preventing renal disorder to at least one part of the surface of a kidney, wherein the part of the surface is uncovered by a fibrous capsule of the kidney. The present invention also provides a cell sheet composition for inhibiting progression of or preventing renal disorder, the cell sheet composition comprising a cell that has a function of producing a hepatocyte growth factor (HGF). The present invention also provides a method of producing a cell sheet composition for inhibiting progression of or preventing renal disorder.

Abstract: The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45° C., (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45° C.; and also provides a layered cell sheet obtained by the method.

Abstract: Provided is a LYPD1 inhibitor for promoting vascular endothelial network formation in a biological tissue. Also provided is a medicinal composition, said medicinal composition comprising a LYPD1 inhibitor as an active ingredient, for treating and/or preventing neoangiogenic disorders. Also provided is a method which comprises: (a1) a step for providing a cell population containing first cells expressing LYPD1 and vascular endothelial cells; (a2) a step for treating the cell population obtained in step (a1) with a LYPD1 inhibitor; and (a3) a step for culturing the cell population obtained in step (a2).